Optical Coherence Tomography- Versus Angiography-Guided Magnesium Bioresorbable Scaffold Implantation in NSTEMI Patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The purpose of a bioresorbable scaffold (BRS) is to provide radial support during coronary healing.

Why It Was Studied

In this study, coronary artery healing after optical coherence tomography (OCT)- versus angiography-guided magnesium BRS (MBRS) implantation in patients with non-ST-segment-elevation myocardial infarction (NSTEMI) is compared.

The Coronary Artery Healing Process after Optical Coherence Tomography Guided Percutaneous Coronary Intervention with Magmaris Bioresorbable Scaffold in Patients with Non-ST-Segment-Elevation Myocardial Infarction: (HONEST) trial is registered with ClinicalTrials.gov, NCT03016624.

Who Took Part

According to the abstract, 75 patients were involved.

75 patients were randomized 1:1 to OCT- or angiography-guided implantation of a MBRS with protocolled pre- and post-dilation.

In the OCT-guided group, prespecified criteria indicating additional intervention were (1) scaffold under-expansion, (2) strut malapposition, (3) edge dissection, and (4) residual stenosis at distal or proximal reference segments.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

The primary endpoint was OCT-derived healing stage at 6 months.

What Was Measured

PubMed files the paper under topics including Absorbable Implants, Coronary Angiography, Coronary Vessels, Magnesium, Non-ST Elevated Myocardial Infarction, Percutaneous Coronary Intervention and Prosthesis Design.

Author keywords: Bioresorbable scaffolds, NSTEMI and Optical coherence tomography.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 75 patients.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Cardiovascular revascularization medicine : including molecular interventions), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.